Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 2, 2013, Pages 453-461

  Hellmann, Matthew D ^a   Chaft, Jamie E ^a   Rusch, Valerie ^b   Ginsberg, Michelle S ^b   Finley, David J ^b   Kris, Mark G ^a   Price, Katharine A R ^a   Azzoli, Christopher G ^a   Fury, Matthew G ^a   Riely, Gregory J ^a   Krug, Lee M ^a   Downey, Robert J ^b   Bains, Manjit S ^b   Sima, Camelia S ^b   Rizk, Nabil ^b   Travis, William D ^b   Rizvi, Naiyer A ^a   Paik, Paul K ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adjuvant therapy; Bevacizumab; Clinical trial; Hemoptysis; Non small cell lung cancers; Squamous cell lung cancers

Indexed keywords

BEVACIZUMAB; CISPLATIN; DOCETAXEL;

ACUTE HEART INFARCTION; ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CANCER SURGERY; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL EXAMINATION; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE SEQUENCE; DRUG SAFETY; EDEMA; EPISTAXIS; FAINTNESS; FATIGUE; FEMALE; GINGIVA BLEEDING; HEMOPTYSIS; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERNATREMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPONATREMIA; KIDNEY DYSFUNCTION; LUNG FUNCTION TEST; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; TREATMENT CONTRAINDICATION;

ADENOCARCINOMA; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; FEMALE; HEMOPTYSIS; HUMANS; KARNOFSKY PERFORMANCE STATUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE CARE; TREATMENT OUTCOME;

EID: 84880919781     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2219-5     Document Type: Article

References (33)

1. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186
2. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674
3. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A, Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR, Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S (2001) Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 7:1194-1201 (Pubitemid 33063774)
4. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669-676 (Pubitemid 36749215)
5. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401-410 (Pubitemid 37328844)
6. Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358:2039-2049 (Pubitemid 351656458)
7. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L (2006) VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 7:359-371
8. Koo PJ, Morgensztern D, Boyer JL, Herbst RS (2012) Targeting vascular endothelial growth factor in patients with squamous cell lung cancer. J Clin Oncol 30:1137-1139
9. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550 (Pubitemid 44917502)
10. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27:1227-1234
11. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191 (Pubitemid 41095154)
12. Crino L, Dansin E, Garrido P, Griesinger F, Laskin J, Pavlakis N, Stroiakovski D, Thatcher N, Tsai CM, Wu YL, Zhou CC (2010) Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 11:733-740
13. Novotny WF, Holmgren E, Griffing S, Johnson D, De Vore R, Kabbinavar F (2001) Identification of squamous cell histology and central, cavitary tumors as possible risk factors for pulmonary hemorrhage (PH) in patients with advanced NSCLC receiving bevacizumab (BV). Proc Am Soc Clin Oncol 20:1318
14. Sandler AB, Schiller JH, Gray R, Dimery I, Brahmer J, Samant M, Wang LI, Johnson DH (2009) Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol 27:1405-1412
15. Miller RR, McGregor DH (1980) Hemorrhage from carcinoma of the lung. Cancer 46:200-205 (Pubitemid 10080459)
16. Reck M, Barlesi F, Crino L, Henschke CI, Isla D, Stiebeler S, Spigel DR (2012) Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts. Ann Oncol 23:1111-1120
17. Chaft JE, Rusch V, Ginsberg MS, Paik PK, Finley DJ, Kris MG, Price KAR, Azzoli CG, Fury MG, Riely GJ, Krug LM, Downey RJ, Bains MS, Sima CS, Rizk N, Travis WD, Rizvi NA (2013) Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable non-squamous non-small cell lung cancers. J Thorac Oncol 8(8) (in press)
18. Chaft JE, Rekhtman N, Ladanyi M, Riely GJ (2012) ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma. J Thorac Oncol 7:768-769
19. Incorperated G (2011) Avastin (bevacizumab) intravenous infusion [package insert]. In: California SF (ed) http://www.accessdata.fda.gov/drugsatfda-docs/ label/2011/125085s225lbl.pdf
20. Meyerhardt JA, Li L, Sanoff HK, Carpenter Wt, Schrag D (2012) Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol 30:608-615
21. Hainsworth JD, Fang L, Huang JE, Karlin D, Russell K, Faoro L, Azzoli C (2011) BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer. J Thorac Oncol 6:109-114
22. Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, Abrao Miziara JE, Balint B, De Marinis F, Keller A, Aren O, Csollak M, Albert I, Barrios CH, Grossi F, Krzakowski M, Cupit L, Cihon F, Dimatteo S, Hanna N (2010) Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 28:1835-1842
23. Scagliotti GV, Vynnychenko I, Park K, Ichinose Y, Kubota K, Blackhall F, Pirker R, Galiulin R, Ciuleanu TE, Sydorenko O, Dediu M, Papai-Szekely Z, Banaclocha NM, McCoy S, Yao B, Hei YJ, Galimi F, Spigel DR (2012) International, randomized, placebo-controlled, double-blind phase III study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: MONET1. J Clin Oncol 30:2829-2836
24. Herbst RS, Sun Y, Eberhardt WE, Germonpre P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, Qin S, Zhang L, Biesma B, Heymach JV, Langmuir P, Kennedy SJ, Tada H, Johnson BE (2010) Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 11:619-626
25. de Boer RH, Arrieta O, Yang CH, Gottfried M, Chan V, Raats J, de Marinis F, Abratt RP, Wolf J, Blackhall FH, Langmuir P, Milenkova T, Read J, Vansteenkiste JF (2011) Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 29:1067-1074
26. Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, Ferry D, Mulatero C, Whorf R, Thompson J, Barlesi F, Langmuir P, Gogov S, Rowbottom JA, Goss GD (2011) Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 29:1059-1066
27. Lee JS, Hirsh V, Park K, Qin S, Blajman CR, Perng RP, Chen YM, Emerson L, Langmuir P, Manegold C (2012) Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 30:1114-1121
28. Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D, Zukin M, Walde D, Laberge F, Vincent MD, Ellis PM, Laurie SA, Ding K, Frymire E, Gauthier I, Leighl NB, Ho C, Noble J, Lee CW, Seymour L (2010) Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 28:49-55
29. Laurie SA, Solomon BJ, Seymour L, Ellis PM, Goss GD, Shepherd FA, Boyer MJ, Arnold AM, Clingan P, Laberge F, Fenton D, Hirsh V, Zukin M, Stockler MR, Lee CW, Chen EX, Montenegro A, Ding K, Bradbury PA, Group NCT (2012) A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC): NCIC Clinical Trials Group study BR29. J Clin Oncol 30(suppl):7511
30. Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y, Yasumoto K (1998) Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 115:1007-1014 (Pubitemid 28224393)
31. Volm M, Koomagi R, Mattern J (1997) Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer 74:64-68 (Pubitemid 27157857)
32. Zhan P, Wang J, Lv XJ, Wang Q, Qiu LX, Lin XQ, Yu LK, Song Y (2009) Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol 4:1094-1103
33. Pajares MJ, Agorreta J, Larrayoz M, Vesin A, Ezponda T, Zudaire I, Torre W, Lozano MD, Brambilla E, Brambilla C, Wistuba II, Behrens C, Timsit JF, Pio R, Field JK, Montuenga LM (2012) Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung. J Clin Oncol 30:1129-1136